Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Olink Bioscience Launches Proseek® Multiplex

Published: Thursday, March 14, 2013
Last Updated: Thursday, March 14, 2013
Bookmark and Share
Company introduces scalable protein biomarker assays based on PEA platform.

Olink has launched Proseek® Multiplex - a new generation of multiplexed protein biomarker immunoassays based on its proprietary Proximity Extension Assay (PEA) platform.

Until now, it has been impossible to scale up conventional assays due to increased antibody cross-reactivity when large numbers of assays are run simultaneously.

Now with the introduction of Proseek Multiplex, biomarker researchers can quantify 92 proteins in just one microliter sample without compromising data quality or performance.

"We are very proud at Olink to introduce a new and scalable era in immunoassays. Proseek has harnessed the tools that have fueled genomics for many years and put them to use in protein biomarker research. In a few years, we aim to offer the market’s most comprehensive portfolio of protein biomarker assays." says Simon Fredriksson, CEO of Olink Bioscience.

First in the range is Proseek Multiplex Oncology I 96x96, a ready-to-use kit sold by Olink capable of analyzing 96 samples against a panel of analytes such as growth factors, inflammatory markers, soluble receptors, and cancer antigens.

Further Proseek 92-plex panels for cardiovascular disease, inflammation, and diabetes will be introduced through 2013.

Minimal sample consumption makes Proseek Multiplex especially suitable for retroactively mining precious biobanked serum samples for novel multivariate biomarker signatures.

It can also provide novel biomarker insights from sample types such as tissue lysates of needle biopsies and micro dialysis samples.

Even in these small samples Proseek Multiplex can provide accurate quantification below pico-gram per milliliter levels.

Proseek is based on the proprietary PEA technology developed at Olink.

PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons each ID-barcoding their respective antigens.

Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR.

"This is major breakthrough. Suddenly the extremely sensitive, reproducible and reliable qPCR workflow since long established as the gold standard for DNA, mRNA, and microRNA analyses has become available also for the measurement of proteins. During our early access period we have established robust SOPs for the entire workflow from sample preparation to data analysis, and it will be a great pleasure supporting our clients with this exceedingly powerful new technology to advance their research." says Professor Mikael Kubista, founder of TATAA Biocenter and renowned for his pioneering work in real time-PCR.

Proseek Multiplex is for research use only. Not for use in diagnostic procedures.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Protein Teams Activate T-Cells
Caltech researchers have discovered T-cell genetic switching is controlled by four proteins acting in a multi-tiered fashion.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
Go-Between Immune Cell is Key to Priming the Body’s Fight Against Cancer
‘Antigen-presenting cell’ activates T cells by alerting them to the presence of tumors.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!